Income Statement
XERIS BIOPHARMA HOLDINGS, INC.
XERS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
291.85 | 203.07 | 163.91 | 110.25 | 49.59 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
291.85 | 203.07 | 163.91 | 110.25 | 49.59 |
|
Operating Expenses
|
266.95 | 236.72 | 207.92 | 192.19 | 164.75 |
|
Research & Development
|
31.17 | 25.56 | 22.34 | 20.97 | 25.16 |
|
Selling, General & Administrative
|
182.37 | 163.48 | 146.10 | 137.75 | 125.72 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
24.90 | -33.65 | -44.01 | -81.94 | -115.16 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
4.74 | 5.32 | 4.75 | 2.58 | 0.31 |
|
Interest Expense
|
- | - | 26.61 | 15.33 | 7.20 |
|
Other Non-Op Income / Expense
|
-24.34 | -23.46 | -19.49 | -14.14 | -7.57 |
|
Income Before Tax
|
0.55 | -57.10 | -63.50 | - | - |
|
Income Tax Expense
|
0.00 | -2.27 | -1.25 | -1.42 | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
0.55 | -54.84 | -62.26 | -94.66 | -122.73 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
26.21 | -32.42 | -42.52 | -80.54 | -113.83 |
|
Earnings Per Share (Basic)
|
0.00 | -0.37 | -0.45 | -0.70 | - |
|
Diluted EPS
|
0.00 | -0.37 | -0.45 | -0.70 | - |
|
Weighted Average Shares
|
160.43 | 146.77 | 137.67 | 135.63 | - |
|
Diluted Weighted Avg Shares
|
172.74 | 146.77 | 137.67 | 135.63 | - |
|
Comprehensive Income
|
0.55 | -54.84 | -62.26 | -94.65 | -122.76 |